Education
About Us
Working with TipRanks
Follow Us
Roche Holding (RHHBY)
OTHER OTC:RHHBY
RHHBY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$34.10 - $44.31
Previous CloseN/A
Volume3.10M
Average Volume (3M)1.42M
Market Cap
$259.05B
Enterprise Value$293.72B
Total Cash (Recent Filing)$8.81B
Total Debt (Recent Filing)$36.17B
Price to Earnings (P/E)23.5
Beta0.41
Next Earnings
Jan 29, 2026EPS Estimate
1.43Last Dividend Ex-Date
Mar 28, 2025Dividend Yield3.33%
Share Statistics
EPS (TTM)1.74
Shares Outstanding5,620,501,500
10 Day Avg. Volume1,462,281
30 Day Avg. Volume1,415,989
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue4.92
Enterprise Value/Gross Profit6.68
Enterprise Value/Ebitda16.69
Forecast
1Y Price Target
$43.00Price Target Upside5.21% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.
Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Roche Holding News
RHHBY FAQ
What was Roche Holding’s price range in the past 12 months?
Roche Holding lowest stock price was $34.10 and its highest was $44.31 in the past 12 months.
What is Roche Holding’s market cap?
Roche Holding’s market cap is $259.05B.
When is Roche Holding’s upcoming earnings report date?
Roche Holding’s upcoming earnings report date is Jan 29, 2026 which is in 158 days.
How were Roche Holding’s earnings last quarter?
Roche Holding released its earnings results on Jul 24, 2025. The company reported $1.742 earnings per share for the quarter, beating the consensus estimate of $1.689 by $0.053.
Is Roche Holding overvalued?
According to Wall Street analysts Roche Holding’s price is currently Undervalued.
Does Roche Holding pay dividends?
Roche Holding pays a Annually dividend of $1.363 which represents an annual dividend yield of 3.33%. See more information on Roche Holding dividends here
What is Roche Holding’s EPS estimate?
Roche Holding’s EPS estimate is 1.43.
How many shares outstanding does Roche Holding have?
Roche Holding has 5,620,501,500 shares outstanding.
What happened to Roche Holding’s price movement after its last earnings report?
Roche Holding reported an EPS of $1.742 in its last earnings report, beating expectations of $1.689. Following the earnings report the stock price went up 0.729%.
Which hedge fund is a major shareholder of Roche Holding?
Currently, no hedge funds are holding shares in RHHBY
Roche Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.00 (5.21% Upside)
$43.00 (5.21% Upside)
Blogger Sentiment
Bullish
RHHBY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.51%
12-Months-Change
Fundamentals
Return on Equity
31.98%
Trailing 12-Months
Asset Growth
11.69%
Trailing 12-Months
Company Description
Roche Holding
Roche Holding AG is a Swiss multinational healthcare company that operates in two main divisions: Pharmaceuticals and Diagnostics. Founded in 1896, Roche is a leader in research-focused healthcare, specializing in the development of innovative medicines and diagnostic tools. The Pharmaceuticals division produces a wide range of prescription drugs, particularly in oncology, immunology, infectious diseases, and central nervous system disorders. The Diagnostics division offers a comprehensive portfolio of in-vitro diagnostics and tissue-based cancer diagnostics, enabling healthcare professionals to make informed decisions regarding patient care.
RHHBY Company Deck
RHHBY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated strong financial performance and strategic advancements, particularly in the pharmaceutical segment with robust sales growth and significant pipeline developments. However, there were notable challenges, including the impact of China's pricing reforms on Diagnostics, safety concerns with Elevidys, and mixed trial results for some drugs.View all RHHBY earnings summariesRHHBY Stock 12 Month Forecast
Average Price Target
$43.00
▲(5.21% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.60% Mutual Funds
0.07% Other Institutional Investors
99.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---